Category

News
The domain of EU-PEARL’s research, Integrated Research Platforms (IRPs) and platform trials is relatively new and consequently the vocabulary is still work in progress.  Hence, the need to develop a common understanding and usage of terminology beyond EU-PEARL. With this goal in mind, D2.1. Report on Terminology, References and Scenarios for Platform Trials and Master...
Read More
As the biomedical sector rapidly mobilizes to address the novel coronavirus pandemic, we are encouraged to see the strong embrace of collaboration, master protocols and platform studies, all in the spirit of delivering the most useful information in the fastest way possible to save lives. The most prominent example is the launch of the adaptive...
Read More
Patient centricity is at the core of EU-PEARL’s mission. That is why we are engaging with patients from the start to co-design the platform trial framework, thus bringing on board more patient-relevant outcomes. Making clinical trials more efficient and patient friendly can ensure that individuals find the clinical trial that matches their needs, that companies...
Read More
Physician, specialised in internal medicine, infectious diseases and epidemiology/public health. EU-PEARL’s scientific co-coordinator, giving support to Dr Joan Genescà. He is part of the VHIR team. How and why did you become involved in EU-PEARL? I have been passionately engaged in research ever since the early stages of my career combining my work as a...
Read More
On 29 May, EU PEARL launched a call for testimonials to collect feedback on patient’s experience participating in clinical trials. If you have participated in a clinical trial and have feedback to share, you can write to us in 3-5 sentences about your experience. Your testimonial will be shared on the EU PEARL and EPF...
Read More
The EU-PEARL project aims to shape future drug development through a systematic approach that enables patient focused, cross company collaborative platform trials The EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) is a unique public-private strategic partnership focused on creating a framework to set up adaptive clinical trial platforms of the future EU-PEARL hopes to transform clinical...
Read More
EU-PEARL kick-off meeting took place in November 21st and 22nd, 2019. Barcelona welcomed over 120 participants, in representation of EU-PEARL partners, associated collaborators, Innovative Medicines Initiative (IMI2) project officer and European Medicines Agency (EMA) The meeting served the purpose of aligning all members with the project’s objectives, work plan and interdependences which will allow EU-PEARL...
Read More
The Innovative Medicines Initiative has approved a 26 million euros project to advance in the development of a framework for platform trials. EU-PEARL aims to improve health outcomes for patients by transforming the way clinical trials are conducted. To this end, a strategic alliance between the public and private sector composed of 36 partners will...
Read More